Co-Diagnostics raises $3M through private placement
What's the deal? Co-Diagnostics, a molecular diagnostics company listed on Nasdaq, announced a $3M private placement priced at-the-market under Nasdaq rules. The deal lets the company sell shares directly to investors at the current market price rather than at a discount.
Why now? Private placements priced at-the-market allow small-cap companies to raise capital quickly without the dilutive pressure of discounted offerings. For a diagnostics firm navigating a post-pandemic market where COVID-19 testing demand has dropped sharply, securing fresh funds is a matter of survival and runway extension.
What could go wrong? A $3M raise is modest, and existing shareholders face dilution. If the company can't grow revenue from its non-COVID product lines, it may need to return to the capital markets again soon — potentially on less favourable terms.
The signal: Small diagnostics companies that rode the pandemic wave are now scraping for capital to fund pivots into new product areas. At-the-market private placements have become a go-to tool for micro-cap firms looking to raise money without the cost and delay of a full public offering.
Read more: prnewswire.com
